NASDAQ false 0001420565 0001420565 2024-08-20 2024-08-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 20, 2024

 

 

Aileron Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-38130   13-4196017
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

12407 N. Mopac Expy., Suite 250 #390  
Austin, Texas   78758
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (737) 802-1989

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.001 par value per share   ALRN   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 20, 2024, Aileron Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders to consider and vote upon the matters listed below. The following is a summary of the matters voted on at that meeting.

 

1.

The stockholders of the Company elected Brian Windsor, Ph.D. and Alan A. Musso as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders. The results of the stockholders’ vote with respect to such matter were as follows:

 

Name  

For

  

Withheld

  

Broker
Non-Votes

Brian Windsor, Ph.D.

   7,828,121   24,847   3,442,389

Alan A. Musso

   7,828,044   24,924   3,442,389

 

2.

The stockholders of the Company approved, on a non-binding advisory basis, the Company’s named executive officer compensation. The results of the stockholders’ vote with respect to such matter were as follows:

 

For

      

Against

      

Abstain

      

Broker
Non-Votes

7,326,953

     109,458     416,557     3,442,389

 

3.

The stockholders of the Company ratified the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect to such matter were as follows:

 

For

      

Against

      

Abstain

10,817,251

     61,696     416,410

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.    Description
104    Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AILERON THERAPEUTICS, INC.
Date: August 21, 2024     By:  

/s/ Brian Windsor

      Brian Windsor, Ph.D.
      President and Chief Executive Officer
v3.24.2.u1
Document and Entity Information
Aug. 20, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001420565
Document Type 8-K
Document Period End Date Aug. 20, 2024
Entity Registrant Name Aileron Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38130
Entity Tax Identification Number 13-4196017
Entity Address, Address Line One 12407 N. Mopac Expy.
Entity Address, Address Line Two Suite 250
Entity Address, Address Line Three #390
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78758
City Area Code (737)
Local Phone Number 802-1989
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol ALRN
Entity Emerging Growth Company false
Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Aileron Therapeutics Charts.
Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Aileron Therapeutics Charts.